We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You canĀ read more about our cookies before you choose.
Etanercept and adalimumab for the treatment of deficiency of adenosine deaminase type 2 (aged 5 years and older)
Etanercept and adalimumab are both recommended to be available as routine commissioning treatment options for deficiency of adenosine deaminase type 2 (DADA2) within the criteria set out in these documents.